2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Solidion Technology reported third-quarter 2026 results, with revenue of $41,638 compared with $9,350 a year earlier and net income of approximately $244,000 compared with a net loss of $4.1 million in the prior-year period. Cash and cash equivalents were $26.2 million at September 30, 2026, and total liabilities fell about 40% from year-end 2025, which the company says supports its capacity to pursue acquisitions.
Q3 2026 revenue was $41,638, up from $9,350 in Q3 2025; basic EPS was $0.02 versus a loss of $1.33 per share.
Net income was approximately $244,000 for the quarter, compared with a net loss of $4.1 million in the prior-year period.
Cash and cash equivalents were $26.2 million at September 30, 2026, down from $27.7 million at June 30, 2026.
On September 13, 2026, the Board authorized repurchases of up to $1.0 million of common stock.
Mueller Water Products furnished an updated investor presentation dated November 11, 2026, which reports results for the fiscal year ended September 30, 2026. Net sales were $1,475.0 million, up from $1,429.7 million in FY2025, and net income rose to $221.9 million from $191.7 million. Shareholders get a fuller view of profit and cash flow, which the company says reflects a third consecutive year of record results.
FY2026 net sales of $1,475.0 million, compared with $1,429.7 million in FY2025.
Net income of $221.9 million, or $1.41 per diluted share, compared with $191.7 million, or $1.22 per share.
Adjusted EBITDA of $372.2 million, compared with $326.2 million; adjusted EPS of $1.57, compared with $1.31.
Free cash flow of $207.3 million, compared with $172.0 million; strategic reorganization and other charges were $27.8 million.
Consolidated Water reported third-quarter 2026 revenue of $30.9 million, down 11.9% from $35.1 million, with lower services and manufacturing revenue partly offset by higher retail and bulk revenue. Net income attributable to company stockholders fell to $2.3 million, or $0.14 per diluted share, from $5.5 million, or $0.34 per diluted share, a year earlier, so shareholders saw both lower sales and lower per-share profit.
Q3 2026 revenue $30.9 million, down 11.9% from $35.1 million; services revenue fell 31.7% to $9.8 million and manufacturing revenue fell 39.7% to $2.8 million
Q3 net income attributable to stockholders $2.3 million ($0.14 diluted EPS) vs $5.5 million ($0.34) in Q3 2025
Nine-month revenue $93.8 million, down 8.5%; cash and cash equivalents $129.2 million as of September 30, 2026
QVC Group said it will file its third-quarter fiscal 2026 results on Form 10-Q with the SEC on Monday, November 16, 2026. The company will also post an audio review of the results on its investor relations website, led by Interim CEO and Chairman Mike George and CFO Bill Wafford. The announcement gives shareholders the filing date and review format but no financial figures.
Form 10-Q for the quarter ended September 30, 2026 to be filed Monday, November 16, 2026
Audio recording reviewing results to be posted to the investor relations website
Review to be led by Interim CEO and Chairman Mike George and CFO Bill Wafford
The 8-K and press release were furnished under Regulation FD and are not deemed filed
Vista Gold said it will release financial results for the quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will hold a conference call that day at 8:00 a.m. MST (10:00 a.m. EST). This notice is a scheduling announcement only and contains no financial figures, so it gives shareholders no new information on results.
Quarter ended September 30, 2026 results to be released before market open on November 12, 2026
Conference call set for November 12, 2026 at 8:00 a.m. MST (10:00 a.m. EST)
Audio replay available through November 30, 2026; call archived at www.vistagold.com after November 12
The filing reports no revenue, earnings, or guidance figures
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Douglas Elliman reported third-quarter 2026 net income of $7.4 million, or $0.08 per diluted share, compared with a net loss of $24.7 million a year earlier, while revenue fell to $252.1 million from $262.8 million. Adjusted EBITDA was a $5.3 million loss versus $1.0 million of income, and the company also approved a $10 million share repurchase program, which it says will be funded from cash on hand.
Q3 2026 revenue was $252.1 million vs. $262.8 million in Q3 2025; the company sold its property management business in October 2025.
Q3 operating income was $6.3 million vs. an operating loss of $10.7 million; Adjusted EBITDA was a $5.3 million loss vs. $1.0 million of income.
Nine-month revenue was $749.9 million vs. $787.6 million, and the net loss narrowed to $11.6 million ($0.14 per share) from $53.3 million ($0.63 per share).
The Board approved a $10 million share repurchase program; cash and a Treasury bill totaled about $123 million with no long-term debt as of September 30, 2026.
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.
Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.
Bain Capital Specialty Finance (BCSF) reported third-quarter 2026 net investment income of $27.7 million, or $0.43 per share, down from $28.6 million, or $0.44 per share, in the second quarter. Net increase in net assets from operations rose to $0.26 per share from $0.22, while net asset value per share fell to $16.49 from $16.65. The company also declared a fourth-quarter dividend of $0.42 per share and appointed Amrit Kanwal as an independent director, expanding the board to nine members.
Q3 2026 net investment income was $27.7 million, or $0.43 per share, versus $28.6 million, or $0.44 per share, in Q2 2026; total investment income was $59.9 million, versus $62.3 million.
Net increase in net assets from operations was $16.7 million, or $0.26 per share, versus $0.22 per share in Q2 2026; net asset value per share was $16.49 at September 30, 2026, versus $16.65 at June 30, 2026.
Board declared a fourth-quarter 2026 dividend of $0.42 per share, with a record date of December 15, 2026 and payment on or before December 29, 2026.
Amrit Kanwal, 61, was appointed an independent Class III director effective November 4, 2026, and joined the Audit, Nominating and Corporate Governance, and Compensation Committees.
Nine Energy Service reported third quarter 2026 revenue of $142.0 million, essentially unchanged from the second quarter's $141.8 million. Net loss widened to $5.1 million, or $(0.36) per share, from $4.9 million, or $(0.35) per share, and adjusted EBITDA fell to $8.3 million from $8.6 million. For shareholders, the company expects fourth quarter revenue to be flat and profitability to be modestly higher than the third quarter.
Q3 2026 revenue of $142.0 million versus $141.8 million in Q2 2026; cementing revenue rose 11% quarter over quarter.
Net loss of $5.1 million ($0.36 per share) in Q3 2026 versus $4.9 million ($0.35 per share) in Q2 2026.
Adjusted EBITDA of $8.3 million in Q3 2026 versus $8.6 million in Q2 2026.
Management expects Q4 2026 revenue to be flat and profitability to be modestly higher than Q3; total liquidity was $46.0 million at September 30, 2026.
Exodus Movement reported third quarter 2026 revenue of $32.5 million, up 7% from $30.3 million a year earlier, but swung to a net loss of $8.3 million attributable to the company from net income of $17.0 million in the prior-year quarter. General and administrative expenses rose 94% to $28.9 million, and the company said it expects to cut combined annual costs by about $30 million going into 2027 following the Monavate and Baanx acquisitions.
Q3 2026 revenue was $32.5 million, up 7% from $30.3 million in Q3 2025
Net loss attributable to Exodus was $8.3 million, versus net income of $17.0 million a year earlier
Adjusted EBITDA was a loss of $3.9 million, compared with positive $5.9 million in Q3 2025
Exodus is on track to reduce combined annual costs by about $30 million going into 2027
EquipmentShare reported third-quarter 2026 results for the period ended September 30, 2026, with total revenue up 55% year over year to $1,468 million and net income of $20 million, compared with $6 million a year earlier. Adjusted Core EBITDA rose 40% to $594 million, and management said it is confident in its full-year 2026 outlook and sees an opportunity to outperform it. For shareholders, both headline revenue and profit grew, though GAAP net income remains small relative to revenue and interest expense was $88 million in the quarter.
Total revenue rose 55% to $1,468 million from $945 million; Rental Segment revenue rose 49% to $1,113 million.
Net income was $20 million versus $6 million; Adjusted Net Income, which excludes $26 million of IPO Founders Awards stock compensation, was $46 million.
Adjusted Core EBITDA increased 40% to $594 million; net leverage fell to 3.4x from 3.7x a year earlier.
Current 2026 guidance ranges include total revenue of $5,808 million to $6,045 million and Adjusted Core EBITDA of $2,136 million to $2,224 million.
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
GMR Solutions reported third quarter 2026 net revenue of $1,595.6 million, up 5.9%, and net income of $135.6 million, up 81.7%, and updated its full year 2026 guidance. Adjusted EBITDA rose 4.2% to $356.6 million in the quarter, but nine-month Adjusted EBITDA grew only 0.4%, and the filing does not state the prior guidance, so the direction of the update cannot be judged from it.
Q3 2026 net revenue $1,595.6 million, up 5.9% from $1,506.9 million; net income $135.6 million, up from $74.6 million
Q3 2026 Adjusted EBITDA $356.6 million, up 4.2%; nine-month Adjusted EBITDA $946.1 million, up 0.4%
Updated full year 2026 guidance: net revenue $5,900 million to $6,050 million; Adjusted EBITDA $1,135 million to $1,195 million
Liquidity of approximately $999.3 million at September 30, 2026, including $298.0 million of cash; $200.0 million of term loan repaid in a September 17, 2026 repricing
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
Bally's preliminary third-quarter 2026 consolidated revenue rose 21.7% year over year to $807.6 million, with growth led by Bally's Intralot B2C and North America Interactive. The company said it expects to file a Rule 12b-25 extension and its Form 10-Q within the extension period, and the figures remain subject to its close process. The results are preliminary and unaudited, so shareholders should watch for the final 10-Q.
Preliminary Q3 2026 revenue was $807.6 million, up from $663.7 million a year earlier
Bally's Intralot B2C revenue rose 22.8% to $257.5 million, while its Adjusted EBITDAR fell to $77.0 million from $86.4 million
The company expects to file a Rule 12b-25 extension and its 10-Q within the extension period
On October 1, 2026, Bally's closed Bronx project financing, receiving $400 million with $160 million more available for future draws
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Bakkt reported third-quarter 2026 revenue of $149.2 million, down 62.9% from $402.2 million a year earlier, mainly due to lower crypto trading volume and the loss of clients. The company posted net income of $14.3 million, or $0.31 per diluted share, versus a net loss of $14.9 million in Q3 2025, and the filing notes the result includes a $26.8 million non-cash gain on the Transchem warrants. It reiterated a full-year 2026 Total Transacting Volume target of approximately $3 billion and set a first-half 2027 target of approximately $6 billion.
Q3 2026 total revenue was $149.2 million versus $402.2 million in Q3 2025; net income attributable to Bakkt was $14.3 million, or $0.31 per diluted share
Adjusted EBITDA loss narrowed to $11.8 million from $14.8 million in Q3 2025 on a consistent basis
TTV was $147.9 million for Q3 2026; the company reiterated its approximately $3 billion full-year 2026 target and set an approximately $6 billion first-half 2027 target
Cash, cash equivalents and restricted cash were $37.3 million as of September 30, 2026, versus $50.7 million as of June 30, 2026
Ranger Energy Services reported third quarter 2026 revenue of $162.8 million, up from $128.9 million a year earlier but down from $176.5 million in the second quarter, with net income of $2.5 million or $0.10 per diluted share. The company also declared a quarterly dividend of $0.06 per share, payable December 4, 2026, which signals continued cash returns to shareholders.
Q3 2026 revenue was $162.8 million, versus $176.5 million in Q2 2026 and $128.9 million in Q3 2025
Net income was $2.5 million, or $0.10 per diluted share, versus $0.29 per diluted share in Q2 2026 and $0.05 in Q3 2025
Adjusted EBITDA was $20.1 million, down from $28.6 million in Q2 2026 but up from $16.8 million in Q3 2025
Quarterly dividend of $0.06 per share payable December 4, 2026, to holders of record on November 20, 2026
Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per share, up from $26.0 million, or $0.35 per share, a year earlier, as research and development spending rose. Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, which the company says should fund planned clinical milestones and operations into 2028.
Q3 2026 net loss was $32.4 million ($0.27 per share), versus $26.0 million ($0.35 per share) in Q3 2025; weighted average shares rose to 120.7 million from 74.3 million.
Research and development expenses were $26.1 million, up from $20.3 million; general and administrative expenses were $8.3 million, up from $7.7 million.
Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, versus about $145 million at December 31, 2025.
On October 2026, the FDA granted Fast Track Designation to PSV359 for FAP-positive solitary fibrous tumors.
JBS N.V. reported third-quarter 2026 results on November 9, 2026. Net sales rose 1% from a year earlier to $22.7 billion, but IFRS adjusted EBITDA fell 36% to $1,181 million and earnings per share fell to $0.15 from $0.52. Net leverage rose to 3.54x from 2.39x, which shows weaker profit and higher debt relative to earnings.
Net sales of $22.7 billion, up 1% from $22.6 billion in 3Q25
IFRS adjusted EBITDA of $1,181 million, down 36%; adjusted EPS of $0.16 vs. $0.54
Free cash flow was negative $167 million in 3Q26 vs. positive $383.5 million in 3Q25
Revolving credit facility raised to $4.2 billion from $3.5 billion; total liquidity of $8.2 billion
Viant Technology reported third-quarter 2026 revenue of $110.4 million, up 29% year-over-year, and adjusted EBITDA of $19.8 million, up 24%. GAAP net income attributable to Viant fell to $67 thousand, or $0.00 per share, from $996 thousand, or $0.06 per share, a year earlier. The board also raised the share repurchase authorization by $50 million to $150 million total, with $70.8 million remaining.
Q3 2026 revenue was $110.4 million, up 29% from $85.6 million; GAAP net income attributable to Viant was $67 thousand, down 93%
Non-GAAP adjusted EBITDA was $19.8 million, up 24%; non-GAAP diluted EPS was $0.13 versus $0.12
Q4 2026 guidance: revenue of $130.5 million to $133.5 million and adjusted EBITDA of $31.0 million to $32.0 million
Repurchase authorization increased by $50 million to $150 million, effective November 9, 2026, with $70.8 million remaining
Green Dot reported third-quarter 2026 results, with GAAP total operating revenues up 21% year over year and a narrower net loss. Adjusted EBITDA rose 9%, but non-GAAP diluted EPS fell 17%. The company will not hold an earnings call or give 2026 guidance because of its pending sale to Smith Ventures and CommerceOne, which is expected to close by the first quarter of 2027.
Third-quarter GAAP total operating revenues were $601.1 million, up 21% from $494.8 million a year earlier.
GAAP net loss was $7.4 million, or $0.13 per diluted share, compared with a net loss of $30.8 million, or $0.56 per share, in the prior-year quarter.
Adjusted EBITDA was $25.8 million, up 9%, while non-GAAP diluted EPS was $0.05 compared with $0.06 a year earlier.
No 2026 financial guidance or earnings call, due to the proposed transactions; the 2026 Annual Meeting is set for December 21, 2026.
Trevi Therapeutics reported a third-quarter 2026 net loss of $21.5 million, or $0.13 per share, up from $11.8 million, or $0.08 per share, a year earlier, as research and development expenses rose to $19.1 million from $10.1 million. The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities and said this funds cash runway into 2030, which matters to shareholders because spending is rising and the filing shows no revenue line.
Net loss of $21.5 million for the quarter ended September 30, 2026, versus $11.8 million in the same period of 2025
Research and development expenses of $19.1 million, up from $10.1 million, driven by Phase 3 OCEAN-1 and OCEAN-2 and Phase 2b LAKE trials
Cash, cash equivalents and marketable securities of $299.4 million at September 30, 2026; the company expects cash runway into 2030
Positive FDA meeting in October 2026 on the non-IPF ILD program; Phase 2 dose-ranging trial expected to start in the first quarter of 2027
Babcock & Wilcox reported third quarter 2026 revenue of $290.8 million, up from $139.2 million a year earlier, and net income of $93.9 million, up from $35.1 million. Net income was lifted by an $85.1 million change in the fair value of customer warrants, and adjusted net income was $4.8 million. The company reiterated its 2026 Adjusted EBITDA target of $80.0 million to $105.0 million and issued a 2027 Adjusted EBITDA target of $125 million to $140 million.
Q3 2026 revenue of $290.8 million vs. $139.2 million in Q3 2025; Adjusted EBITDA of $17.7 million vs. $9.4 million
Net income of $93.9 million includes an $85.1 million change in fair value of customer warrants; adjusted net income was $4.8 million
Basic EPS of $0.61 vs. $0.30 in Q3 2025; Q3 bookings of $228 million and backlog of $2.5 billion
2026 Adjusted EBITDA target of $80.0 million to $105.0 million reiterated; 2027 target of $125 million to $140 million issued
Office Properties Income Trust reported results for the quarter ended September 30, 2026, with a net loss of $45.8 million, or $2.09 per share, and normalized FFO of $20.5 million, or $0.93 per share. Rental income rose to $114.2 million from $109.1 million a year earlier, and the company sold 13 properties in the quarter and issued $425 million of new senior secured notes.
Rental income was $114.2 million for the quarter, up from $109.1 million in the same quarter of 2025.
Net loss was $45.8 million, or $2.09 per share, and normalized FFO was $20.5 million, or $0.93 per share.
Same property cash basis NOI was $51.5 million, a 14.8% increase year over year.
Issued $425 million of 8.75% senior secured notes due 2031 and repaid a $325 million revolving credit facility and a $100 million term loan due January 2027.
Gladstone Investment Corporation reported net investment income of $4.8 million, or $0.12 per share, for the quarter ended September 30, 2026, down from $15.9 million, or $0.40 per share, in the prior quarter. Total investment income fell 14.8% to $24.2 million, while the net increase in net assets from operations rose to $17.1 million, helped by net unrealized appreciation, and net asset value per share rose to $16.43 from $16.24.
Net investment income was $4.8 million, or $0.12 per share, versus $15.9 million, or $0.40 per share, in the June 30, 2026 quarter.
Total investment income was $24.2 million, down from $28.4 million, mainly due to a $5.6 million decrease in success fee income.
Net increase in net assets from operations was $17.1 million, or $0.43 per share, compared with a decrease of $11.9 million, or $0.30 per share, in the prior quarter.
The quarterly distribution was $0.24 per share, unchanged from the prior quarter, and Walter H. Wilkinson Jr. resigned from the board on October 22, 2026.
Rackspace Technology reported third-quarter 2026 revenue of $609 million, down 9.3% from a year earlier, with Public Cloud revenue down 17.2% and Private Cloud revenue up 4.2%. The net loss narrowed to $54 million, or $0.21 per share, from $67 million, or $0.28 per share, a year earlier. The company raised its full-year 2026 revenue outlook by $35 million at the midpoint and kept its non-GAAP operating profit and Adjusted EBITDA outlook unchanged.
Q3 2026 revenue was $609 million, down 9.3% from $671 million in Q3 2025; Public Cloud fell 17.2% to $349 million and Private Cloud rose 4.2% to $260 million.
Net loss narrowed to $54 million ($0.21 per share) from $67 million ($0.28 per share); non-GAAP operating profit rose 12% to $36 million.
Full-year 2026 total revenue outlook is $2.51 billion to $2.56 billion, raised by $35 million at the midpoint; the profit outlook was maintained.
As of September 30, 2026, cash and cash equivalents were $108 million and total liquidity was $170 million; Q3 capital expenditures were $104 million.
P3 Health Partners reported third quarter 2026 revenue of $396 million, up 15% from a year earlier, and net income of $30.8 million versus a net loss of $69.5 million in the prior-year quarter. The company raised the low end of its full-year 2026 Adjusted EBITDA guidance to $90 million, moving the midpoint to $100 million, though the quarter also benefited from payer settlements and prior-year development.
Q3 2026 total revenue was $396 million, up 15% from $345 million a year earlier.
Q3 2026 Adjusted EBITDA was $20.9 million, compared with a loss of $45.9 million in Q3 2025.
Full-year 2026 Adjusted EBITDA guidance is now $90 million to $110 million, up from a lower low end.
Q3 medical margin of $43.9 million included favorable payer settlements; excluding these items it was $35.0 million.
U.S. Physical Therapy furnished a transcript of its November 5, 2026 third-quarter earnings call, in which it reported revenue up 13% to $223 million and adjusted earnings per share of $0.80, up $0.14 from a year earlier. It reaffirmed full-year EBITDA guidance of $102 million to $106 million, but reported a GAAP loss per share of $1.04 versus earnings of $0.48 a year earlier, which the company attributed to changes in the value of partner ownership stakes in subsidiaries.
Q3 2026 total revenue was $223 million, up 13%; comparable revenue rose 7%.
Q3 2026 EBITDA was $28 million, up $4 million; adjusted EPS was $0.80, up $0.14.
GAAP net income attributable to shareholders was $11 million, versus $13 million a year earlier, and GAAP loss per share was $1.04.
Full-year 2026 EBITDA guidance of $102 million to $106 million was reaffirmed; credit facility borrowings were $247 million versus $162 million at year-end 2025.
AbCellera reported third-quarter 2026 results, with total revenue of $10.6 million versus $9.0 million a year earlier and a net loss of $40.8 million, or $(0.13) per share, down from $57.1 million, or $(0.19) per share. The company said it had over $890 million in total available liquidity as of September 30, 2026, including a $200 million share offering that closed August 14, 2026 at $9.75 per share.
Total revenue of $10.6 million in Q3 2026, compared with $9.0 million in Q3 2025
Net loss of $40.8 million, or $(0.13) per share, compared with $57.1 million, or $(0.19) per share, in Q3 2025
R&D expenses of $43.5 million, down from $55.0 million; SG&A expenses of $13.6 million, down from $25.0 million
Positive top-line Phase 2 data for ABCL635 announced in Q3; Phase 1 top-line data for ABCL575 announced after quarter end
FutureFuel reported third-quarter 2026 results on November 9, 2026. Revenue rose 361% to $104.7 million, driven by biofuel volume and pricing, and the net loss narrowed to $8.4 million from $9.2 million, although the company still posted a gross loss and a shrinking cash balance. The company expects positive Adjusted EBITDA in the fourth quarter and for full-year 2026, after a nine-month Adjusted EBITDA loss of $6.9 million.
Q3 2026 total revenue was $104.7 million, up from $22.7 million in Q3 2025; biofuel revenue was $87.8 million.
Net loss was $8.4 million, or $0.19 per diluted share, compared with a $9.2 million net loss in Q3 2025.
Q3 Adjusted EBITDA was a loss of $4.9 million; the company expects fourth-quarter Adjusted EBITDA of approximately $7 million.
Cash and cash equivalents were $21.3 million at September 30, 2026, down from $34.3 million at June 30, 2026.
Coherus Oncology reported third quarter 2026 net revenue from continuing operations of $14.3 million, up from $11.6 million a year earlier, and a narrower net loss from continuing operations of $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share. The company also announced a strategic prioritization plan that focuses tagmokitug development on esophageal cancer and reduces headcount by about 30%, with the CFO saying these benefits will be realized over the next two quarters.
Q3 2026 net revenue from continuing operations was $14.3 million, versus $11.6 million in Q3 2025; LOQTORZI revenue was $14.0 million, up 25% from $11.2 million.
Q3 2026 GAAP net loss from continuing operations was $38.9 million, or $(0.25) per share, versus $44.5 million, or $(0.38) per share, in Q3 2025.
Right-sizing reduces headcount by about 30% and is expected to lower core cash burn by $6 million to $7 million per quarter.
Cash, cash equivalents and marketable securities were $83.6 million at September 30, 2026, versus $172.1 million at December 31, 2025.
Infinity Natural Resources reported third quarter 2026 results, with total revenues of $197.6 million, up from $79.7 million a year earlier, and a net loss of $0.4 million, compared with net income of $40.0 million in the same quarter of 2025. The company also narrowed its 2026 capital and production guidance, and the net loss was driven in part by $63.2 million of mark-to-market hedge losses.
Total revenues were $197.6 million for the quarter ended September 30, 2026, versus $79.7 million a year earlier.
Net loss was $(0.4) million, or $(0.37) per basic share, compared with net income of $40.0 million, or $0.67 per basic share, in Q3 2025.
Adjusted EBITDAX, a non-GAAP measure, was $137.7 million, versus $60.0 million a year earlier; the company called this a record.
2026 guidance was narrowed: development capital expenditures of $450 million to $475 million and net production of 355 to 375 MMcfe/d.
Cannae Holdings released its third quarter 2026 results on November 9, 2026, posting them on its website and in a shareholder letter, with a conference call scheduled for 5:00pm Eastern that day. The letter highlights a 70% drop in holding company expenses, $111 million of year-to-date share buybacks, and $793 million of proceeds from noncore asset sales since the start of 2025, though the excerpt does not state consolidated third quarter revenue, profit or per-share figures.
Holding company expenses fell $58.8 million, or 70%, in the first nine months of 2026 compared with 2025.
Year to date in 2026, Cannae repurchased 7.7 million shares for $111 million, representing 16.4% of shares outstanding, and paid $20 million in dividends.
Proceeds from noncore asset sales totaled $793 million from the beginning of 2025 through the third quarter of 2026.
Two directors will not stand for re-election at the December 11, 2026 annual meeting, and the board will shrink to ten members afterward.
Lincoln Educational Services reported third-quarter 2026 revenue of $159.2 million, up 12.6% from $141.4 million, with net income of $4.7 million, up from $3.8 million. The company raised its full-year 2026 revenue guidance to $600.0 million to $605.0 million while reiterating its adjusted EBITDA guidance of $76.0 million to $80.0 million.
Q3 2026 revenue of $159.2 million, up from $141.4 million; net income of $4.7 million, up from $3.8 million
Diluted EPS of $0.15 versus $0.12; adjusted EBITDA of $17.4 million, up 30.8%
2026 revenue guidance raised to $600.0 million to $605.0 million; student start growth guidance narrowed to 10% to 12%
Board raised the share repurchase authorization by $30 million to $70 million total, with more than $37 million remaining
Surrozen reported a third-quarter 2026 net loss of $129.7 million, up from $71.6 million a year earlier, with no related-party research revenue after the TCGFB collaboration ended. Most of the loss came from non-cash fair value changes in tranche and warrant liabilities, and the company said October financings lifted pro forma cash to about $220.3 million, with runway into 2029.
Net loss was $129.7 million for the quarter ended September 30, 2026, including a $73.9 million non-cash loss on the tranche liability.
Research service revenue from a related party was zero, compared with $1.0 million a year earlier, after the TCGFB collaboration terminated effective November 2025.
Cash and cash equivalents were $100.4 million at September 30, 2026; pro forma cash was about $220.3 million after October financings.
The company plans to expand DUET Phase 2a enrollment from about 60 to 150 patients, with Phase 1b topline data expected in the second half of 2027.
BitGo reported third-quarter 2026 results on November 9, 2026. Total revenue fell to $2.9 billion, down 50.9% from a year earlier, driven mainly by lower digital asset sales in a soft crypto trading environment. Net income rose to $44.1 million, but the filing attributes it mainly to a $71.5 million unrealized gain on the company's digital asset treasury, and adjusted EBITDA was a loss of $4.3 million.
Total revenue of $2.9 billion, down 50.9% year-over-year and 34.1% sequentially
Net income of $44.1 million, versus a net loss of $19.0 million in Q2 2026, driven by a $71.5 million unrealized gain on digital assets
Adjusted EBITDA loss of $4.3 million, compared with a $13.5 million profit in Q3 2025
Repurchased $24.7 million of common stock during the quarter under a $50 million authorization
ImageneBio reported third quarter 2026 results, with a net loss of $15.6 million, or $0.91 per share, down from $24.8 million, or $2.91 per share, a year earlier. The company had no revenue in either period, and lower research and development and general and administrative expenses drove the smaller loss. It ended the quarter with $126.6 million in cash, cash equivalents and marketable securities, which it expects will fund planned operations into the first quarter of 2028.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $24.8 million a year earlier.
Net loss per share was $0.91, compared with $2.91 a year earlier.
R&D expenses fell to $11.3 million from $15.2 million, and G&A expenses fell to $6.0 million from $11.0 million.
Cash position was $126.6 million as of September 30, 2026, with funding expected into the first quarter of 2028.
Atea Pharmaceuticals reported a third-quarter 2026 net loss of $32.2 million, or $0.40 per share, down from $42.0 million, or $0.53 per share, a year earlier, as research and development spending fell. The company also secured a credit facility with Hercules Capital of up to $200 million, of which $65 million was drawn on November 6, 2026, and said current resources fund operations into mid-2028.
Net loss was $32.2 million, or $0.40 per share, for the three months ended September 30, 2026, versus $42.0 million, or $0.53 per share, a year earlier.
Cash, cash equivalents and marketable securities were $191.2 million at September 30, 2026, versus $301.8 million at December 31, 2025.
Hercules Capital facility of up to $200 million; $65 million drawn at closing on November 6, 2026, with up to $135 million more subject to milestones.
Phase 3 C-BEYOND trial met its primary endpoint: 93.91% SVR for BEM/RZR versus 94.75% for Epclusa; C-FORWARD topline results expected in early 2027.
Lineage reported third-quarter 2026 results with total revenue down 1.2% to $1.36 billion, a GAAP net loss of $173 million ($0.68 per diluted share, versus a $0.44 loss a year earlier), and adjusted EBITDA down 7.0% to $317 million. CEO Greg Lehmkuhl said higher oil prices, constrained trucking capacity and tariff uncertainty created headwinds later in the quarter, and the company adjusted its full-year guidance to reflect pressures it expects to continue into the fourth quarter.
Q3 2026 AFFO fell 14.9% to $188 million, and AFFO per share fell 14.1% to $0.73.
Full-year 2026 guidance: adjusted EBITDA of $1.25 billion to $1.27 billion and AFFO per share of $2.86 to $2.98; the filing does not show prior guidance figures.
Quarterly dividend declared at $0.5325 per share, an annualized rate of $2.13 per share.
Same-store occupancy grew year over year for the second consecutive quarter; the conference call is on November 10, 2026, at 8:00 a.m. Eastern Time.
FreightCar America reported third quarter 2026 revenue of $76.5 million, down from $160.5 million a year earlier, and delivered 662 railcars versus 1,304. It posted adjusted EBITDA of $0.1 million and an adjusted net loss of $9.5 million, or $(0.28) per diluted share, compared with adjusted net income of $7.8 million a year earlier. The company reaffirmed its fiscal 2026 outlook, which matters to shareholders because it signals that management still expects the full-year targets it set on October 19.
Q3 2026 revenue was $76.5 million versus $160.5 million in Q3 2025; railcar deliveries were 662 units versus 1,304.
Adjusted EBITDA was $0.1 million (0.2% margin) versus $15.9 million (9.9% margin) a year earlier.
Backlog reached 2,660 units valued at $284.5 million at September 30, 2026, up 28% from $222.0 million.
Fiscal 2026 outlook reaffirmed: 3,100 to 3,300 railcars, revenue of $370 to $410 million, and adjusted EBITDA of $15 to $19 million.
HF Foods reported third-quarter 2026 results on November 9, 2026. Net revenue rose 4.1% to $319.6 million, helped by the Searay Foods acquisition completed August 31, 2026, but the company posted a GAAP net loss of $4.2 million compared with $0.9 million a year earlier. Adjusted net income fell 52.1% to $2.1 million, which shows that higher fuel costs and operating expenses outweighed the revenue gain for shareholders.
Net revenue was $319.6 million, up from $307.0 million a year earlier; the company called it its seventh consecutive quarter of year-over-year net revenue growth.
GAAP net loss was $4.2 million, or $0.08 per share, versus a net loss of $0.9 million in the prior-year quarter.
Adjusted net income fell 52.1% to $2.1 million, and adjusted EBITDA fell 6.3% to $11.0 million.
Searay Foods contributed $4.2 million of net revenue and about $0.6 million of adjusted EBITDA for the one month since its August 31, 2026 acquisition.
AMCON Distributing reported results for the fiscal year ended September 30, 2026, with diluted earnings per share of $2.52 compared with $0.62 in the prior year. Sales rose to $3.12 billion from $2.82 billion, and the retail health food segment posted an operating loss while the wholesale segment reported operating income.
Net income available to common shareholders was $2.4 million, compared with $0.6 million in fiscal 2025.
Sales were $3.12 billion, compared with $2.82 billion in fiscal 2025.
Wholesale distribution segment operating income was $25.5 million; retail health food segment operating loss was $0.6 million.
Shareholders' equity was $117.0 million at September 30, 2026.
Verde Clean Fuels reported third-quarter 2026 results, with a net loss of $2.0 million, or $(0.04) per Class A share, compared with a net loss of $2.3 million, or $(0.06) per share, a year earlier. The company attributed the smaller loss mainly to cost savings, partly offset by higher share-based compensation, and reported $52.6 million in cash and no debt as of September 30, 2026.
Q3 2026 net loss of $2.0 million vs. $2.3 million in Q3 2025; diluted loss per Class A share of $(0.04) vs. $(0.06)
Nine-month 2026 net loss of $6.3 million vs. $7.6 million in the same period of 2025; loss per share of $(0.14) vs. $(0.21)
Cash and cash equivalents of $52.6 million and no debt as of September 30, 2026
The company said it continues to evaluate strategic alternatives and opportunities to deploy its STG+ technology
Alta Equipment Group reported third-quarter 2026 revenue of $417.4 million, down 1.2% from a year earlier, while its net loss available to common stockholders narrowed to $12.2 million from $42.3 million. Adjusted EBITDA rose 7.7% to $44.9 million, and the company revised its full-year 2026 Adjusted EBITDA guidance to a range of $165.0 million to $170.0 million. Shareholders get lower losses and higher adjusted profit, alongside a slight sales decline.
Q3 total revenue was $417.4 million versus $422.6 million a year earlier; organic revenue fell 0.7%.
Basic and diluted net loss per share was $(0.37), compared with $(1.31) in the prior-year quarter.
Material Handling equipment bookings rose 67% year over year, and backlog continued to grow.
Full-year 2026 Adjusted EBITDA guidance was revised to $165.0 million to $170.0 million.
AlTi Global reported third-quarter 2026 results in an investor presentation furnished under Item 2.02 and Item 7.01. Revenue edged up 1% year over year, operating expenses fell 25%, and the net loss from continuing operations narrowed sharply, which points to improved profitability for shareholders. The filing contains no guidance update.
Revenue was $58 million, up 1% from $57.2 million a year earlier, with management fees up 7% to $55 million
Total operating expenses fell 25% year over year to $64 million
Operating loss narrowed to $6 million from $28.5 million a year earlier; net loss from continuing operations was $11.4 million versus $87.0 million
Adjusted EBITDA was $6.2 million, up 1% year over year, with a 10.8% margin
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.